Exploring the Science and Appreciating the Patient Experience: Early, Individualized Therapy to Optimize Outcomes in Multiple Sclerosis
September 11, 2019
September 11, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
Supported by individual educational grants from Biogen MA, Inc and Novartis Pharmaceuticals Corporation. This activity was supported by an educational grant from Celgene Corporation
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This program is intended for multiple sclerosis (MS) specialists, neurologists, internists, and allied healthcare professionals involved in the care and management of patients with MS.
MS is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This expert-faculty video discussion activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this interactive case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared-decision making (SDM).
Upon completion of this activity, participants should be better able to:
- Describe current perspectives regarding early, efficacious treatment of active MS disease to prevent irreversible neurologic damage
- Compare the mechanisms of action and efficacy of currently available and emerging MS treatments in order to better individualize patient treatment plans
- Design therapeutic strategies encompassing patient efficacy outcomes, safety and tolerability considerations, reimbursement strategies and consideration, as well as patient preferences, when selecting a DMT
- Implement a multidisciplinary treatment strategy involving shared decision-making along with appropriate patient resources to improve the management of patients with MS
Aaron L. Boster, MD
Systems Medical Chief, Neuroimmunology
OhioHealth Neurological Physicians
Claire Riley, MD
Assistant Professor of Neurology
Medical Director, Columbia MS Center
Columbia University Irving Medical Center
New York, New York
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Aaron Boster, MD
- Consulting Fees: EMD Serono, Genentech, Genzyme
- Speakers’ Bureaus: EMD Serono, Genentech, Genzyme
- Contracted Research: Biogen MA, Inc., Genentech, Johnson & Johnson
Claire Riley, MD
- Consulting Fees: Biogen MA, Inc., EMD Serono, TG Therapeutics
The Integrity Continuing Education, Inc. planners and their spouses/life partners have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of September 11, 2019 through September 11, 2020 participants must:
- Read the activity information and front matter
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.